Zacks Research Has Negative Outlook for CPRX FY2025 Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of Catalyst Pharmaceuticals in a research note issued on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of $2.02 for the year, down from their previous forecast of $2.07. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ FY2026 earnings at $2.25 EPS and FY2027 earnings at $2.37 EPS.

Several other equities research analysts have also issued reports on the stock. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reissued an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $25.72 on Monday. The stock’s fifty day moving average is $22.53 and its 200 day moving average is $21.72. The firm has a market capitalization of $3.12 billion, a PE ratio of 21.80, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals has a fifty-two week low of $14.47 and a fifty-two week high of $26.16.

Insiders Place Their Bets

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its position in shares of Catalyst Pharmaceuticals by 9.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after acquiring an additional 33,888 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after buying an additional 50,888 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth approximately $1,185,000. Finally, Redhawk Wealth Advisors Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $1,273,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.